New vaccine strategy could shield spleenless patients from deadly infection
NCT ID NCT04166656
First seen Nov 20, 2025 · Last updated Jun 20, 2026 · Updated 30 times
Summary
This phase 3 trial is testing three different ways to give the meningococcal B vaccine to adults who have had their spleen removed. People without a spleen are at higher risk for serious infections. The study will compare how well each vaccine schedule triggers an immune response and how safe they are. 84 participants will be randomly assigned to one of the three strategies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPLENECTOMY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
I-REIVAC/CIC1417 Cochin Hospital, AP-HP
RECRUITINGParis, 75014, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Meningococcal B vaccines (Trumenba and Bexsero)
What this could lead to
If successful, this could identify the most effective vaccine schedule to protect people without a spleen from a life-threatening meningococcal infection.
What could go wrong
This is a relatively small trial (84 people) and results may not apply to all asplenic patients. Different vaccine responses are possible, and the study only measures short-term immune response, not long-term protection.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.